Vor bio presents positive data update on trem-cel at hsct² conference

Cambridge, mass., nov. 09, 2023 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in vbp101, its phase 1/2a multicenter, open-label, first-in-human study of trem-cel (vor33) in patients with acute myeloid leukemia (aml). guenther koehne, md, phd, deputy director and chief of blood & marrow transplant and hematologic oncology at miami cancer institute of baptist health south florida will present these data on november 10, 4:15pm pst, in an oral presentation at the astct/ebmt 6th international conference on relapse after transplant and cellular therapy (hsct²) in los angeles, california.
VOR Ratings Summary
VOR Quant Ranking